Developing First-in-Class RNA Oncology Therapeutics
TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. Our lead therapeutic candidate, that we believe has blockbuster potential, targets an RNA molecule which has been shown to be the driver of metastatic disease across multiple tumor types and has been validated pre-clinically in our lab at MGH. Our initial FIH clinical study, for which an eIND filing is planned for Q1 of 2022, is intended to provide positive proof-of-mechanism for the TTX platform. We believe that demonstrating our ability to overcome the challenge of RNA delivery to genetic targets outside the liver would represent a major step forward in unlocking therapeutic access to genetic targets involved in a range of cancers. We intend to build a broad and diverse pipeline of therapeutics and diagnostics with the potential to reach previously undruggable genetic targets that are well documented. We have a robust IP portfolio, experienced team, including a high profile and active scientific and medical advisory board, to execute our plan and we are highly capital efficient.
|
Solving for RNA delivery in oncology
Modular toolbox enabling rational drug design
|
Lead Therapeutic Candidate
Targeting miR-10b to treat metastatic cancer
|
|
Research and Development
Building a broad and diverse oncology pipeline
|
Corporate
|